Red Jacket: Dr. Mark Goldberg, a clinical innovator

Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

By Alexandra Pecci • Oct. 27, 2023

The 2023 Red Jacket honorees

This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

By Meagan Parrish • Oct. 27, 2023

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Red Jacket: Dr. Jeremy Levin, a transformational leader

A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.

By Michael Gibney • Oct. 27, 2023

Red Jacket: Helen Sabzevari, an immunotherapy pioneer

Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

By Meagan Parrish • Oct. 27, 2023

Red Jacket: Ken Getz, a champion of clinical trials

Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

By Alexandra Pecci • Oct. 27, 2023

Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

Express Scripts sued by independent pharmacies over alleged price fixing

The Cigna-owned pharmacy benefit manager colluded with rival Prime Therapeutics to overcharge pharmacies, according to a lawsuit filed last week.

By Rebecca Pifer • Oct. 25, 2023

Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

Pfizer’s new shot approval adds to a growing vaccine prowess

Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.

By Michael Gibney • Oct. 24, 2023

Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

By Michael Gibney • Oct. 19, 2023

PharmaVoice 100s: Clinical trial gurus

Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.

By Meagan Parrish • Oct. 19, 2023

For women’s health, Organon changed the financial language

Organon is partnering with governments, banks, NGOs and investors on programs to improve women’s health through results-based financing.

By Alexandra Pecci • Oct. 18, 2023

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

The FDA might yank cold medicines from shelves — and that could be just the beginning

Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.

By Alexandra Pecci • Oct. 17, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

Has the science of anti-aging caught up with the dream of a longer life?

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

By Kelly Bilodeau • Oct. 16, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

PharmaVoice 100s: Patient heroes

Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access. 

By Karissa Waddick • Oct. 13, 2023

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

By Michael Gibney • Oct. 12, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

PharmaVoice 100s: Tech wizards

The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

By Karissa Waddick • Oct. 9, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023